Institute for Myeloma and Bone Cancer Research Announces Upcoming Oral and Poster Presentations at the 2008 American Society of Hematology (ASH) Annual Meeting
Two oral presentations and three poster presentations will be offered by researchers from the Institute for Myeloma and Bone Cancer Research celebrating the 50th Annual Meeting of the American Society of Hematology (ASH).
LOS ANGELES, CA November 17, 2008 — Institute for Myeloma and Bone Cancer Research (IMBCR) today announced that data regarding ongoing research on cancer stem cells in myeloma, new proteasome inhibitors, targeted therapy using RNA sequences specific to the myeloma cells, anti-angiogenic compounds and anti-myeloma effects of a new form of vincristine sulfate will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH). The meeting will be held Dec. 6-9, 2008, at the Moscone Convention Center in San Francisco, California.
Oral presentations include:
1) Characterization of Cancer Stem Cells in Multiple Myeloma
Authors: Haiming Chen,1 Mingjie Li,1 Eric Sanchez,1 Cathy S. Wang,1 Ariana Berenson,1 Jennifer Li1 Jeffrey Steinberg,1 James Wang,1 Jing Shen1, Zhiwei Li1, Benjamin Bonavida,2 and James R Berenson1
2) The Novel Proteasome Inhibitor CEP-18770 Inhibits Myeloma Tumor Growth In Vitro and In Vivo and Enhances the Anti-MM Effects of Melphalan, Doxorubicin and Arsenic Trioxide
Authors: Eric Sanchez,1 Richard A Campbell,1 Jeffrey Steinberg,1 Mingjie Li,1 Haiming Chen,1 Benjamin Bonavida,2 and James R Berenson1
Poster presentations include:
1) A Novel Targeted Therapeutic Approach to Multiple Myeloma Using Tumor Specific Anti-Sense RNA Sequences
Authors: Zhi-Wei Li1, Dror Shalitin1, Jing Shen1, Michael Share1, Mingjie Li1, Cathy S. Wang1, Eric Sanchez1, Jeffery Steinberg1, Haiming Chen1, Benjamin Bonavida2, and James R. Berenson1
2) A Novel Method for Screening Anti-Angiogenic Compounds: The Chorionicallantoic Membrane (CAM)/Feather Bud (FB) Assay
Authors: Haiming Chen, 1 Cathy S. Wang,1 Mingjie Li,1 Eric Sanchez,1 Jennifer Li1 Ariana Berenson,1 Jeffrey Steinberg,1 Hang Chen,1 Jing Shen1, Zhiwei Li1, Benjamin Bonavida,2 and James R Berenson,1
3) Anti-tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in SCID-hu Models of Multiple Myeloma
Authors: Eric Sanchez,1 Zhiwei Li,1 Haiming Chen,1 Benjamin Bonavida,2 Steven Deitcher,3 Anne Hagey,3 and James R Berenson,1
- The Institute for Myeloma & Bone Cancer Research, West Hollywood, CA;
- Departments of Microbiology, Immunology and Molecular Genetics, Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA;
- Hana Biosciences, Inc. South San Francisco, CA
The Institute for Myeloma and Bone Cancer Research (IMBCR), established in 2004 as a 501 c (3) non-profit organization, is headquartered in Los Angeles, California. IMBCR is the only independent non-profit cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of the blood cells that reside in the bone marrow.
IMBCR research findings have also been presented at annual meetings of the American Society of Clinical Oncologists (ASCO), and the bi-annual International Myeloma Workshop in Greece. Our research has been published in publications including, Blood, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Oncogene, and the British Journal of Haematology.
Contacts: James R. Berenson, MD, Medical & Scientific Director; email@example.com. Haiming Chen, MD, Ph.D, Director of Research Laboratory firstname.lastname@example.org. Zhi Wei Li, Ph.D, Principal Scientist for “The Cure Myeloma Project” email@example.com. Eric Sanchez, Associate Director Animal Research ; firstname.lastname@example.org. Cheryl A. Cross, MPH, Director of New Research Development; email@example.com.